Coherus Oncology (CHRS) Non-Current Debt (2016 - 2026)
Coherus Oncology (CHRS) posted Non-Current Debt of $37.1 million for Q1 2026, little changed sequentially from $37.1 million in Q4 2025, and up 1.0% YoY from $36.8 million in Q1 2025.
Coherus Oncology (CHRS) Non-Current Debt (2016 - 2026) Analysis & Trends
Coherus Oncology has reported Non-Current Debt for 11 years, with the latest figure at $37.1 million in Q1 2026.
- Quarterly Non-Current Debt rose 1.0% year-over-year to $37.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.1 million (up 1.0% YoY) and the FY2025 annual result came in at $37.1 million, up 0.96% from the prior year.
- Non-Current Debt steadied at $37.1 million in Q1 2026 per CHRS's latest filing, from $37.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $246.5 million in Q4 2023 and troughed at $36.5 million in Q2 2024.
- A 5-year average of $131.4 million and a median of $72.5 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 323.39% in 2022, then plunged 85.14% in 2024.
- Over 5 years, Non-Current Debt stood at $245.5 million in 2022, then gained by 0.41% to $246.5 million in 2023, then plunged by 85.11% to $36.7 million in 2024, then climbed by 0.96% to $37.1 million in 2025, then gained by 0.26% to $37.1 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $37.1 million, $37.1 million, and $37.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 8.96 Bn |
| 10 | Coherus Oncology | 214.42 Mn | 109.12 Mn | 10.07 Mn | 37.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.25 Mn |
| Mar 31, 2026 | 37.15 Mn |
| Dec 31, 2025 | 37.05 Mn |
| Sep 30, 2025 | 36.96 Mn |
| Jun 30, 2025 | 36.87 Mn |
| Mar 31, 2025 | 36.78 Mn |
| Dec 31, 2024 | 36.70 Mn |
| Sep 30, 2024 | 36.62 Mn |
| Jun 30, 2024 | 36.54 Mn |
| Mar 31, 2024 | 72.45 Mn |
| Dec 31, 2023 | 246.48 Mn |
| Sep 30, 2023 | 246.22 Mn |
| Jun 30, 2023 | 245.96 Mn |
| Mar 31, 2023 | 245.72 Mn |
| Dec 31, 2022 | 245.48 Mn |
| Sep 30, 2022 | 245.25 Mn |
| Jun 30, 2022 | 196.04 Mn |
| Mar 31, 2022 | 195.85 Mn |
| Dec 31, 2021 | 75.51 Mn |
| Sep 30, 2021 | 57.92 Mn |